Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models

Vaccine

Volumn 30, Issue 12, 2012, Pages 2187-2196

  Fu, Jie ^a   Zhao, Bijun ^b   Dong, Zhouhuan ^c   Sun, Yunjuan ^a   Luan, Haofei ^a   Shen, Xianfei ^a   Gao, Xin ^a   Gong, Feng ^d   Li, Subo ^d   Song, Haifeng ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Beijing Institute of Blood Transfusion Medicine   (China)

Author keywords

Cytoimmunity; DNA vaccine; Electroporation; Heparanase; Humoral immunity

Indexed keywords

CANCER VACCINE; CD31 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; HEPARANASE; HEPARANASE DNA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; ELECTROPORATION; ENZYME ACTIVITY; FEMALE; GENETIC IMMUNIZATION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; SURVIVAL TIME; T LYMPHOCYTE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; CANCER VACCINES; ELECTROPORATION; FEMALE; GLUCURONIDASE; IMMUNITY, HUMORAL; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 84862810413     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.002     Document Type: Article

References (38)

1. Vlodavsky I., Elkin M., Pappo O., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J 2000, 2(Suppl.):37-45.
2. Zcharia E., Metzger S., Chajek-Shaul T., Friedmann Y., Pappo O., Aviv A., et al. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia 2001, 6(3):311-322.
3. Sommerfeldt N., Beckhove P., Ge Y., Schütz F., Choi C., Bucur M., et al. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 2006, 66(15):7716-7723.
4. Parish C.R., Freeman C., Brown K.J., Francis D.J., Cowden W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999, 59(14):3433-3441.
5. http://clinicaltrials.gov/ct2/results%3Fterm=phosphomannopentaose+sulfate+and+PI88.
6. Basche M., Gustafson D.L., Holden S.N., O'Bryant C.L., Gore L., Witta S., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006, 12(18):5471-5480.
7. Lewis K.D., Robinson W.A., Millward M.J., Powell A., Price T.J., Thomson D.B., et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008, 26(1):89-94.
8. Chen K.S., Zhang L., Tang L., Zhang Y.H., Gao D.L., Yan L., et al. Expression of heparanase mRNA in anti-sense oligonucleotide-transfected human esophageal cancer EC9706 cells. World J Gastroenterol 2005, 11(31):4916-4917.
9. Zhang Z.H., Chen Y., Zhao H.J., Xie C.Y., Ding J., Hou Y.T. Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo. Cancer Biol Ther 2007, 6(4):587-595.
10. Myler H.A., Lipke E.A., Rice E.E., West J.L. Novel heparanase-inhibiting antibody reduces neointima formation. J Biochem 2006, 139(3):339-345.
11. Cai Y.G., Fang D.C., Chen L., Tang X.D., Chen T., Yu S.T., et al. Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro. Tumour Biol 2007, 28(4):238-246.
12. Gan J., Li S.B., Wang X.L., Wang Y.L. Cloning of human heparanse full-length cDNA from hepatoma. Clin Med China 2008, 24(13):97-98. [in Chinese].
13. Li S.B., Gao H.W., Luan H.F., Gao X., Tan Y.X., Wang X.L., et al. Generation of mouse anti-human heparanase polyclonal antibody by genetic immunization. Bull Acad Mil Med Sci 2009, 33(5):92-93. [in Chinese].
14. van Drunen Littel-van den Hurk S., Luxembourg A., Ellefsen B., Wilson D., Ubach A., Hannaman D., et al. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine 2008, 26(43):5503-5509.
15. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27(40):5450-5459.
16. Dobaño C., Widera G., Rabussay D., Doolan D.L. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 2007, 25(36):6635-6645.
17. Wang B.Y., Zhang H., Wang Z.S., Xu B.Q. The treatment of tumors using electroporation of cell's membrane due to EM-pulses with antitumor drugs and the optimal of parameters EM-pulses. J Microw 2006, 22(Supplement):207-211. [in Chinese].
18. Gong Y.Y., Sun Y., Zhao J.F., Tong Z.R., Yuan Q.P., Xu B.Q. Technology of gene pulse transfection and its application to the animal tumor therapy. Life Sci Instrum 2006, 4:46-48. [in Chinese].
19. Chen T., Tang X.D., Wan Y., Chen L., Yu S.T., Xiong Z., et al. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 2008, 10(9):977-986.
20. Kröger A., Ortmann D., Krohne T.U., Mohr L., Blum H.E., Hauser H., et al. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice. Cancer Res 2001, 61(6):2609-2617.
21. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56(1):21-26.
22. Sin J.I., Kim J.M., Bae S.H., Lee I.H., Park J.S., Ryoo H.M. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009, 17(5):906-913.
23. Liu Z.X., Gao H.W., Tian S.G., Zhang Y.P., Gong F. Expression of human heparanase in Pichia yeast expression system. Lett Biotechnol 2007, 18(3):423-425. [in Chinese].
24. Chen Z.T., Wang K.G., Feng J., Wang J., Zhang M.Z., Xu C.S., et al. A serological investigation of four infectious diseases of cattle. J Mountain Agric Biol 2004, 23(3):220-223. [in Chinese].
25. Liu J.Q., Shen L.J. Purification of rat and rabbit anti-Trichinella spiral IgG antibody from serum using caprylic acid-Ammonium sulfate (CA-AS). J Pathogen Biol 2008, 3(8):595-597. [in Chinese].
26. Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E., et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005, 117(3):444-455.
27. Tang X.D., Wan Y., Chen L., Chen T., Yu S.T., Xiong Z., et al. H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. Cancer Res 2008, 68(5):1529-1537.
28. Roy M., Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem 2009, 106(2):200-209.
29. Williams B.B., Wall M., Miao R.Y., Williams B., Bertoncello I., Kershaw M.H., et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol Immunother 2008, 57(11):1635-1645.
30. Zhao H., Liu H., Chen Y., Xin X., Li J., Hou Y., et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 2006, 66(17):8779-8787.
31. Cho H.I., Niu G., Bradley N., Celis E. Optimized DNA vaccines to specifically induce therapeutic CD8T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 2008, 57:1695-1703.
32. Bergman P.J., Camps-Palau M.A., McKnight J.A., Leibman N.F., Craft D.M., Leung C., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24(21):4582-4585.
33. Manley C.A., Leibman N.F., Wolchok J.D., Rivière I.C., Bartido S., Craft D.M., et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 2011, 25(January-February (1)):94-99. 10.1111/j.1939-1676.2010.0627.x.
34. Han X.M., Wang H.J., Yang J.M., Zhou Y.L., Tao H.Q., Gao H., et al. Effects of anti-heparanase antibody on the growth and invasion of HCCLM6 human hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi 2009, 31(1):10-14. [Article in Chinese].
35. Gingis-Velitski S., Ishai-Michaeli R., Vlodavsky I., Ilan N. Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J 2007, 21(14):3986-3993.
36. McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 2007, 151(1):1-14.
37. Zhang Y.F., Tang X.D., Gao J.H., Fang D.C., Yang S.M. Heparanase: a universal immunotherapeutic target in human cancers. Drug Discov Today 2011, 16(9-10):412-417.
38. Luan H.F., Fu J., Song H.F. Application of gene introduction in vivo by electroporation in preclinical and clinical trials. Chin Bull Life Sci 2009, 21(3):467-471. [in Chinese].